Alnylam Pharmaceuticals (ALNY) Raw Materials (2018 - 2026)

Alnylam Pharmaceuticals (ALNY) has 9 years of Raw Materials data on file, last reported at $11.7 million in Q1 2026.

• For the quarter ending Q1 2026, Raw Materials fell 50.05% year-over-year to $11.7 million; the trailing twelve-month figure through Mar 2026 stood at $11.7 million (down 50.05% YoY), and the FY2025 full-year result was $14.2 million, down 40.81% from the prior year.
• Raw Materials for Q1 2026 stood at $11.7 million, down from $14.2 million in the prior quarter.
• Across five years, Raw Materials topped out at $26.0 million in Q2 2024 and bottomed at $11.7 million in Q1 2026.
• The 5-year median for Raw Materials is $22.3 million (2022), against an average of $20.9 million.
• Peak annual rise in Raw Materials reached 51.25% in 2022, while the deepest fall reached 72.81% in 2022.
• A 5-year view of Raw Materials shows it stood at $22.3 million in 2022, then gained by 4.62% to $23.3 million in 2023, then rose by 2.65% to $24.0 million in 2024, then plunged by 40.81% to $14.2 million in 2025, then dropped by 17.6% to $11.7 million in 2026.
• The last three Raw Materials figures came in at $11.7 million (Q1 2026), $14.2 million (Q4 2025), and $22.3 million (Q3 2025), per Business Quant data.

Peer Comparison